Moreover, production of nanoparticles with antibodies to target the specific antigen is still of little use for positively targeting nanoparticles to lung cancer, such as Anti-EpCAM, anti-NSE, anti-ganglioside, etc. As a result, continued development of nanoparticles containing monoclonal antibodies is predicted to be successful as a medication delivery mechanism for lung cancer. This evidence concerns the gene ENO2 and lung cancer.